UMike
Klutzing in Thai
- Joined
- 16 January 2007
- Posts
- 1,466
- Reactions
- 1,829
Good afternoon UMike,Got almost 1000 of these basterds. during last year and a bit.
Early on had a $320 target.
This Christmas would of been happy to offload 350 at around $310ish.
Still got ave buy in at $261.77. Only issue is that with a dividend yield of 1.1% there needs to be that capital gain to make it worth while.
Mmmm, as Butch Cassidy was wont to say " but who are these guys? "For the Chartists now
Going to be a bumper second half without the one off costs from Vifor.gotta remember they report in USD and results are expressed in Constant Currency (CC) terms
CSL delivered a net profit after tax of $1.62 billion for the first half of financial year 2023, steady at CC. This included one-off costs associated with the acquisition of Vifor Pharma.
Underlying profit (NPATA attributable to CSL shareholders) was $1.82 billion, up 10% at CC. Revenue was up 25% at CC
• Strong growth in immunoglobulin and albumin sales
• Record levels of plasma collections
• Strong growth in market leading haemophilia B product IDELVION® and key specialty product KCENTRA®
• Strong performance by influenza vaccines business, CSL Seqirus
• Licence agreement for late-stage self-amplifying mRNA vaccine technology
• Successful closure of Vifor acquisition
o ~15% revenue growth
o Integration well underway and cost synergies on track
• HEMGENIX® approved by FDA, the first gene therapy for haemophilia B
• NPATA earnings per share $3.772
• Interim dividend of US$1.07 per share
o Converted to Australian currency, the interim dividend is approximately A$1.55 per share, up 9%
• Guidance reaffirmed – FY23 NPATA anticipated to be in the range of approximately $2.7 billion to $2.8 billion at CC
Problem is that with the rising inflation a 1%-2% dividend doesn't seem so attractive any more........
• Interim dividend of US$1.07 per share
o Converted to Australian currency, the interim dividend is approximately A$1.55 per share, up 9%
• Guidance reaffirmed – FY23 NPATA anticipated to be in the range of approximately $2.7 billion to $2.8 billion at CC
Possibly, but ...Problem is that with the rising inflation a 1%-2% dividend doesn't seem so attractive any more.
TruePossibly, but ...
A) It's a growth stock.
B) the reinvestment into R&D is for the future
C) long term hold.
I'd agree with @Dona Ferentes . If it grows 10, 20, 30 %. pa I don't care what the divi is.True
Not arguing but has been stagnant for the past 3 years and it is why I limited my exposure.
Still holding a lot and prepared to get more if it dips.
Though I expect a good next six months I cannot see massive growth (20%+).
Yes it did. For a $140 billion company, the $300 million trade is sizeable, but not that big a deal. Already $90mill has gone through this next morning. But as its an Asian seller, maybe the money has left the ASX?Well thats when it started to fall away from $295 to $290.5
Annualised, it's double that.That 0.55% Interim dividend doesn't thrill me too much..
....and made it, closing near to the day's high of 300.26. Fourth time we've been here!CSL is approaching $300.
We use cookies and similar technologies for the following purposes:
Do you accept cookies and these technologies?
We use cookies and similar technologies for the following purposes:
Do you accept cookies and these technologies?